Compare Medtronic PLC (MDT) vs MakeMyTrip Ltd (MMYT) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

MakeMyTrip (MMYT) trades at $53.22, down 2.56% on the day, with a bullish technical signal and strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.25 exceeding expectations. Revenue for 2025 reached $978.34 million, though 2026 projections show a potential decline in net profit margin to 4.96%. Cash flow from operations remains healthy at $185.29 million, but a significant increase in liabilities is forecasted for 2026.

The outlook for MMYT is positive based on consistent earnings outperformance and a dominant market position in Indian online travel. Key risks include rising debt levels and travel demand volatility. With 72.73% of analysts rating it a Buy, the stock presents a growth opportunity, but investors must monitor execution against heightened financial leverage in the coming year.